Acquisition ApprovalDistrict Court Judge Jeffrey Cummings ruled against the preliminary injunction sought by the FTC, allowing the proposed acquisition of Surmodics by GTCR to move forward.

Investor ConfidenceThere is an expectation that SRDX stock will rally towards $43 per share following the court's decision, indicating investor confidence.

Market PositionThe Judge found the FTC's argument about the coatings market unpersuasive, suggesting a more favorable market position for Surmodics.

Bears Say

Analyst RatingDespite the legal victory, the analyst maintains a MARKET PERFORM rating as the expected rally towards $43 per share is not seen as investable.

SurModics News

SurModics Completes Merger, Ends Credit Agreement

An update from SurModics ( ($SRDX) ) is now available. On November 19, 2025, SurModics completed a merger...

30d ago

SRDX

Surmodics’ acquisition will not be appealed by FTC

Surmodics (SRDX) expects to close its previously announced its acquisition by an affiliate of GTCR promptly. The Federal...

1M ago

SRDX

Surmodics downgraded to Underperform from Market Perform at Barrington

Barrington analyst Michael Petusky downgraded Surmodics (SRDX) to Underperform from Market Perform given that shares are now trading...

1M ago

SRDX

SurModics Merger with GTCR LLC Clears Legal Hurdle

An announcement from SurModics ( ($SRDX) ) is now available. On November 10, 2025, Surmodics, Inc. announced that...

1M ago

SRDX

Midday Fly By: SoftBank exits Nvidia, CoreWeave cuts guidance

The major averages were mixed near noon, with the S&P 500 and Nasdaq in negative territory amid declines...

1M ago

Morning Movers: Nvidia dips after SoftBank sells out of stake

Stock futures are leveling off. Global equities rose on signs that the United States federal government shutdown may...

1M ago

Surmodics confirms District Court denies request for preliminary injunction

Surmodics (SRDX) “announced that the United States District Court for the Northern District of Illinois has denied a...

1M ago

SRDX

Surmodics acquisition by GTCR can proceed, Reuters reports

Private equity firm GTCR will be allowed to move forward with its acquisition of medical device coatings maker...

1M ago

ITGR

SRDX

SurModics trading halted, news pending

14:45 EST SurModics (SRDX) trading halted, news pending Published first on TheFly – the ultimate source for real-time,...

1M ago

SRDX

Surmodics’ Pounce thrombectomy platform shows efficacy in limb ischemia study

Surmodics (SRDX) announced that results from an analysis of 160 real-world patients with symptomatic infrainguinal limb ischemia from...

2M ago

SRDX

SRDX Earnings Report this Week: Is It a Buy, Ahead of Earnings?

SurModics Inc (SRDX) is scheduled to report 4th quarter earnings on 11/05/2025. Regarding Q4 estimates, Wall Street analysts...

2M ago

SRDX

Surmodics announces results from PROWL registry study

The company states: “Surmodics (SRDX) announced that results from a sex-specific analysis of 160 real-world acute, subacute, and...

2M ago

SRDX

SurModics: Hold Rating Amid Mixed Financial Performance and Legal Uncertainties

Barrington analyst Michael Petusky has maintained their neutral stance on SRDX stock, giving a Hold rating on August...

4M ago

SRDX

SurModics: Balancing Strong Financial Performance with Acquisition Uncertainty

Needham analyst Michael Matson has maintained their neutral stance on SRDX stock, giving a Hold rating on July...

4M ago

SRDX

SRDX FAQ

What was SurModics Inc’s price range in the past 12 months?

Currently, no data Available

What is SurModics Inc’s market cap?

Currently, no data Available

When is SurModics Inc’s upcoming earnings report date?

SurModics Inc’s upcoming earnings report date is Feb 10, 2026 which is in 53 days.

How were SurModics Inc’s earnings last quarter?

Currently, no data Available

Is SurModics Inc overvalued?

According to Wall Street analysts SurModics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SurModics Inc pay dividends?

SurModics Inc does not currently pay dividends.

What is SurModics Inc’s EPS estimate?

SurModics Inc’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SurModics Inc have?

Currently, no data Available

What happened to SurModics Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of SurModics Inc?

Currently, no hedge funds are holding shares in SRDX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SurModics Inc

SurModics, Inc. (SRDX) is a leading provider of medical device and in vitro diagnostic technologies, primarily serving the healthcare industry. The company specializes in developing innovative coating technologies, drug delivery systems, and biomaterials, which are used in various applications such as cardiovascular, ophthalmology, and other specialty markets. SurModics focuses on enhancing the performance and safety of medical devices through its advanced product offerings and services, aimed at improving patient outcomes.